Metsera, Inc. (MTSR)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	n/a
Net Income (ttm)	-169.29M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About MTSR

Metsera is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. We use our proprietary MINT peptide library of NuSH analog peptides alongside our Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and our MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates that we are advancing into clinical trials for obesity or overweight...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2022
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: MTSR
• Website: https://metsera.com/

Financial Performance

Financial numbers in USD